Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast versus placebo in moderate hidradenitis suppurativa
NL-OMON42894Phase 2Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing Apremilast with Placebo (2 arms). Primary endpoints: Inflammatory cytokine protein expression in HS lesional skin and Inflammatory cytokine mRNA expression in HS lesional skin. Started Feb 2017; status: active, not recruiting.
02
Drugs
apremilast
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NL-OMON42894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42894.